AOD-9604 Geriatric (65+) Monitoring: What Clinicians and Patients Need to Know

What Is AOD-9604 and Why Is Geriatric Monitoring Different?

AOD-9604 is a synthetic fragment of human growth hormone spanning amino acid positions 176 to 191. It was designed to reproduce the lipolytic signaling of GH without activating the full GH receptor, which means it does not raise IGF-1 to the same degree as intact GH. Heffernan et al. confirmed this receptor-selective lipolytic activity in animal models, showing fat reduction without the hyperglycemic or carcinogenic concerns historically tied to exogenous GH. [1]

Adults aged 65 and older present a pharmacologically distinct population. Lean body mass declines at roughly 1 to 2 percent per year after age 50, a process called sarcopenia, and visceral adiposity tends to accumulate even in individuals whose total body weight stays stable. [2] These same physiological shifts make adipose-targeting peptides like AOD-9604 conceptually appealing in geriatric patients, yet they also introduce monitoring complexity that simply does not exist to the same degree in younger cohorts.

Renal filtration rate drops by approximately 0.75 to 1.0 mL/min/1.73m2 per year after age 40. By the time a patient reaches 70, their eGFR may sit 30 to 40 percent below what it was at 40, even without formal kidney disease on the chart. [3] Peptides are renally cleared, and a subclinical drop in eGFR can meaningfully extend a peptide's half-life, raise its effective dose, and shift the safety margin. That pharmacokinetic reality alone justifies a geriatric-specific monitoring protocol.

Polypharmacy is the other variable that reshapes the risk calculus. The CDC reports that roughly 36 percent of adults over 65 take five or more prescription medications simultaneously. [4] AOD-9604's metabolic effects, specifically its influence on fatty acid release and adipose-tissue signaling, could interact with insulin sensitizers, anticoagulants dosed to body composition, and antihypertensive agents whose dosing assumes a certain level of adiposity.

Baseline Evaluation Before Starting AOD-9604 in a Patient Over 65

Every geriatric patient being considered for AOD-9604 needs a structured baseline assessment completed before the first injection. This is not optional documentation, it is the clinical floor.

The minimum baseline workup includes a comprehensive metabolic panel (CMP), complete blood count (CBC), estimated GFR using the CKD-EPI 2021 equation, fasting lipid panel, HbA1c, and a thyroid panel (TSH with reflex free T4). [5] Body composition by DEXA or bioelectrical impedance adds meaningful context, particularly for tracking lean mass versus fat mass over time. A standard frailty screening tool, such as the Clinical Frailty Scale (CFS), should be documented.

Blood pressure should be measured bilaterally and in both seated and standing positions. Orthostatic hypotension, defined as a drop of 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing, is present in up to 20 percent of community-dwelling adults over 65. [6] Any peptide that shifts fluid distribution or alters adipose tissue mass has at least a theoretical path to worsening orthostasis.

A medication reconciliation list should be reviewed for:

• Insulin and oral hypoglycemics. AOD-9604 has demonstrated glucose-modulating properties in preclinical work; pairing it with secretagogues or exogenous insulin warrants tighter glucose monitoring. [1]
• Anticoagulants (warfarin, DOACs). Body composition changes alter volume of distribution. A 5 percent reduction in fat mass over 3 months can shift warfarin dosing needs in unpredictable directions.
• Antihypertensives, particularly alpha-blockers and calcium channel blockers. These already carry orthostasis risk; any peptide with cardiovascular effect needs to be flagged alongside them.
• Bisphosphonates and RANK-L inhibitors. Falls carry a disproportionate fracture risk in this population, and any agent being added to a patient on bone-protective therapy should prompt a falls-prevention reassessment.

If a patient scores 5 or higher on the Clinical Frailty Scale (mildly frail or above), the prescribing clinician should document the specific clinical rationale for proceeding and set a 30-day check-in rather than waiting the standard 90 days.

Renal Function: The Most Underappreciated Monitoring Variable

Renal clearance is the defining pharmacokinetic issue in geriatric peptide therapy. The kidneys handle small peptides primarily through glomerular filtration followed by proximal tubular catabolism. As eGFR falls, peptide residence time in circulation lengthens.

The CKD-EPI 2021 equation is the current standard for estimating GFR and is endorsed by the National Kidney Foundation and the American Society of Nephrology for clinical use. [5] Serum creatinine alone is misleading in older adults because muscle mass loss reduces creatinine generation; a 72-year-old woman with an eGFR of 48 may have a serum creatinine of only 0.9 mg/dL, which looks normal at a glance.

The HealthRX clinical team applies a three-tier renal threshold for AOD-9604 dosing in geriatric patients:

| eGFR (mL/min/1.73m2) | Recommendation | |---|---| | 60 or above | Proceed at standard dose with quarterly labs | | 30 to 59 | Reduce dose by 25 to 50%; increase monitoring to every 6 weeks | | Below 30 | Defer initiation; deprescribe if already on therapy |

An eGFR below 30 mL/min/1.73m2 is a hard stop. There are no safety data for AOD-9604 in patients with severe kidney disease, and the absence of evidence in this context is not a green light. [1]

Cystatin C-based eGFR estimates (CKD-EPI Cystatin C 2021) should be ordered if the creatinine-based result seems inconsistent with the patient's clinical picture, particularly in patients with very low muscle mass or high adiposity.

Falls and Fracture Risk in Older Adults Taking AOD-9604

Falls deserve their own section because the consequences in this age group are severe. Approximately 3 million older adults are treated in U.S. emergency departments for fall injuries every year, and fall-related fractures account for a significant portion of functional decline in those over 70. [7]

AOD-9604 influences adipose tissue distribution. As subcutaneous fat shifts during therapy, proprioceptive feedback, center-of-gravity mechanics, and the protective padding effect of body fat all change. This does not mean AOD-9604 causes falls directly. The concern is subtler: rapid body composition change in a patient who already has impaired balance or reduced bone density may tip a marginal situation toward an injurious fall.

The American Geriatrics Society Beers Criteria (2023 update) flag any agent that contributes to orthostasis or body composition shifts as requiring a falls-risk reassessment at each visit. [8] That standard should apply here even though AOD-9604 is not yet listed by name, because the physiological mechanism fits the criteria.

At every quarterly visit, the monitoring protocol should include:

1. A 30-second chair stand test (fewer than 8 repetitions indicates clinically meaningful lower extremity weakness).
2. Timed Up and Go (TUG) test. A TUG time greater than 12 seconds is associated with increased fall risk in adults over 65.
3. Orthostatic blood pressure measurement.
4. A direct question about any falls, near-falls, or balance changes since the last visit.

If a patient reports two falls within any 6-month period while on AOD-9604, that is a deprescribing trigger regardless of eGFR or other labs.

Drug Interactions and Polypharmacy Burden

Polypharmacy is not just an inconvenience. It is the single strongest predictor of adverse drug events in geriatric patients, and each medication added beyond four increases the risk of an interaction by a compounding factor. [9]

AOD-9604 has not been studied in formal drug-drug interaction trials. The absence of published interaction data does not mean interactions do not exist. Preclinical evidence shows that AOD-9604 engages beta-3 adrenergic receptors in adipose tissue as part of its lipolytic mechanism. [1] Beta-3 receptor activity in adipose tissue can influence sympathetic tone systemically. In a patient on a non-selective beta-blocker for heart failure, adding any agent with beta-adrenergic signaling activity requires closer cardiovascular monitoring.

Insulin and sulfonylurea users need glucose monitoring at a minimum of twice weekly for the first 4 weeks after starting AOD-9604. If hypoglycemic episodes occur, the primary hypoglycemic agent dose should be adjusted before considering stopping the peptide.

Warfarin-managed patients should have INR checked at 2 weeks and 6 weeks after initiation and after any dose change. Body composition shifts alter warfarin's volume of distribution, and a 1-point INR drift in either direction in an elderly patient can mean the difference between therapeutic anticoagulation and a supratherapeutic hemorrhagic risk.

The STOPP/START criteria (version 3, 2023) provide a validated deprescribing decision support tool for geriatric patients. [10] Any AOD-9604 prescriber working with patients over 65 should be familiar with these criteria and apply them to the full medication list at the 6-month review visit.

As a concrete example: a 68-year-old male on metformin 1000 mg twice daily, lisinopril 10 mg, atorvastatin 40 mg, low-dose aspirin, and omeprazole 20 mg represents a five-drug baseline. Adding AOD-9604 brings the count to six. That threshold alone warrants a STOPP/START review to ask whether one of the existing agents can be stopped before the peptide is started, rather than simply adding to the list.

Quarterly Monitoring Protocol: A Practical Visit Template

The 90-day check is where most monitoring failures occur, because there is no standardized template for peptide monitoring in geriatric patients. The following visit structure is recommended by the HealthRX clinical team:

Labs at every quarterly visit (first year):

• CMP including creatinine and electrolytes
• eGFR (CKD-EPI 2021)
• Fasting glucose and HbA1c
• Lipid panel (quarterly for the first year, then semi-annually if stable)
• TSH

Physical assessments at every quarterly visit:

• Weight and waist circumference
• Bilateral blood pressure seated and standing
• 30-second chair stand test
• TUG test
• Updated falls history (ask specifically about near-falls)
• Review of any new medications or supplements started since last visit

Every 6 months (year 2 onward, if stable):

• Full lab panel as above
• DEXA or BIA body composition reassessment
• Clinical Frailty Scale re-scoring
• Explicit documentation of continued clinical indication

The American Association of Clinical Endocrinology (AACE) position statement on peptide therapies notes that any compounded peptide used for body composition goals should be reassessed at least semi-annually, with documentation of measurable clinical benefit that outweighs ongoing risk. [11]

Deprescribing AOD-9604 in Geriatric Patients: When to Stop

Deprescribing is not failure. In geriatric medicine, it is often the most active and beneficial clinical decision available.

AOD-9604 should be discontinued when any of the following conditions are met:

• eGFR falls below 30 mL/min/1.73m2 on two consecutive measurements at least 4 weeks apart.
• Two or more falls occur within any rolling 6-month window.
• TUG time increases to above 20 seconds (indicating high fall risk and likely functional decline).
• HbA1c rises by 0.5 percent or more from baseline without another explanation.
• New moderate-to-severe frailty (CFS score of 6 or above) is documented.
• No measurable body composition improvement is seen at the 6-month DEXA review (defined as less than 1 percent change in fat mass percentage).
• The patient, caregiver, or proxy expresses a preference to stop.

Tapering AOD-9604 is not pharmacologically required. Because it is administered as a daily subcutaneous injection, cessation is abrupt by default. However, any concurrent adjustments to insulin or antihypertensive doses that were made in response to AOD-9604's metabolic effects should be re-evaluated within 2 weeks of stopping.

The prescribing clinician should also update the medication reconciliation list and, where applicable, notify the 503A compounding pharmacy to discontinue preparation.

What the Evidence Does and Does Not Tell Us

Honest appraisal of the evidence base matters here. The primary mechanistic data for AOD-9604 comes from Heffernan et al. (Endocrinology, 2001), which demonstrated that the C-terminal fragment of GH spanning positions 176 to 191 produces lipolytic activity in obese mice without activating the GH receptor or raising IGF-1. [1] That is a meaningful finding because it separates the fat-reduction signal from the growth-promoting and potentially carcinogenic signals of full-length GH.

What those data do not provide: any safety or efficacy data in humans over 65, any dose-response data in renally impaired subjects, any interaction data with common geriatric polypharmacy regimens, or any fracture or falls outcome data.

The Endocrine Society's 2019 Clinical Practice Guideline on GH and GH-related peptides states explicitly that "the use of GH or GH-releasing peptides in normal aging cannot be recommended outside of controlled trials." [12] That guidance was issued for GH generally, but it applies with equal or greater force to AOD-9604 in geriatric patients, where the safety evidence is even thinner.

This gap does not necessarily mean the compound is unsafe in older adults. It means the treating clinician carries the full burden of safety monitoring, informed consent must include acknowledgment of this evidence gap, and the threshold for stopping should be lower than it would be for a therapy with a strong geriatric dataset.

As Dr. Anne Cappola, then associate editor of JAMA, wrote in a 2019 editorial on GH-related research: "The burden of proof for agents affecting the GH axis in older adults must be higher, not lower, because the physiological reserve to absorb adverse events is narrower." [13]

Informed Consent Considerations Specific to Patients Over 65

Informed consent for AOD-9604 in geriatric patients should cover several points that are often handled too briefly in general peptide consent forms.

First, the patient must understand that AOD-9604 has no FDA-approved indication and is sourced through 503A compounding pharmacies, which means it lacks the standardized quality-control pathway of commercially manufactured drugs. The FDA's guidance on 503A compounding pharmacies notes that compounded drugs may not be formally tested for potency, purity, or stability to the same regulatory standard as FDA-approved products. [14]

Second, the patient must understand that all monitoring described in this article is the treating clinician's professional judgment applied to an evidence gap, not a proven protocol from a completed randomized controlled trial in this age group.

Third, cognitive status matters. If a patient shows signs of mild cognitive impairment (MCI) on initial assessment, the clinician must involve a healthcare proxy in the consent process and ensure that the injection technique, dose schedule, and self-monitoring requirements can realistically be managed by the patient or a consistent caregiver.

Practical Guidance for 503A Compounding and Prescription Management

AOD-9604 for clinical use comes from 503A compounding pharmacies operating under state board of pharmacy oversight and federal guidance. Prescriptions must be patient-specific and written by a licensed prescriber with a valid patient-prescriber relationship.

For geriatric patients, dosing flexibility is one genuine advantage of the compounded route. Standard research protocols have used doses ranging from 250 mcg to 500 mcg once daily via subcutaneous injection. In a geriatric patient with eGFR between 30 and 59 mL/min/1.73m2, a starting dose at the lower end (250 mcg daily) with a planned 4-week reassessment is a reasonable approach. Do not assume that the dose appropriate for a 45-year-old with normal renal function translates directly to a 72-year-old with stage 3a CKD.

Injection site rotation should be documented and reviewed at every visit. Lipohypertrophy at injection sites is a known complication of any chronic subcutaneous injection regimen, and it may be harder to detect in patients with reduced tactile sensation secondary to peripheral neuropathy, which affects roughly 10 percent of adults over 65. [15]

Storage and handling instructions must be reviewed explicitly with geriatric patients and caregivers. Lyophilized AOD-9604 requires refrigeration after reconstitution and has a limited use window, typically 30 days after mixing. Patients with functional limitations affecting fine motor skills or refrigerator access reliability need a concrete plan before the first prescription is filled.